<DOC>
	<DOC>NCT02317744</DOC>
	<brief_summary>This study will test the effectiveness of the combination of Naltrexone and Bupropion relative to placebo for reducing binge eating in persons with obesity and binge eating disorder.</brief_summary>
	<brief_title>Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Feeding and Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Bupropion hydrochloride, naltrexone hydrochoride drug combination</mesh_term>
	<criteria>Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition) BMI between 30 kg/m2 and 50 kg/m2 Not taking antidepressant medications Read English proficiently enough to read study assessments Available for duration of treatment plus followup period Able to travel to study location (New Haven, CT) for monthly visits Agree to study procedures Medical status judged by study physician as contraindication History of seizures Past or current anorexia nervosa, bulimia nervosa Current medications that influence eating/weight Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality) that requires immediate treatment Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>